Cystatin C-A marker of peripheral atherosclerotic disease?

Atherosclerosis

Volumn 199, Issue 2, 2008, Pages 397-401

  Arpegard J ^a   Ostergren J ^a   de Faire, U ^a,c   Hansson, L O ^b   Svensson, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atherosclerosis; Inflammation; Kidney; Peripheral vascular disease

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; INTERLEUKIN 6;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTHESIS; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CYSTATINS; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 47649090393     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.11.025     Document Type: Article

References (22)

1. Tenstad O., Roald A.B., Grubb A., and Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 56 (1996) 409-414
2. Finney H., Newman D.J., and Price C.P. Adult reference ranges for serum cystatin C. creatinine and predicted creatinine clearance. Ann Clin Biochem 37 Part 1 (2000) 49-59
3. Norlund L., Fex G., Lanke J., et al. Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum beta 2-microglobulin/cystatin C-ratio. Scand J Clin Lab Invest 57 (1997) 463-470
4. Vinge E., Lindergard B., Nilsson-Ehle P., and Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest 59 (1999) 587-592
5. Knight E.L., Verhave J.C., Spiegelman D., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421
6. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51 (2005) 321-327
7. Eriksson P., Deguchi H., Samnegard A., et al. Human evidence that the cystatin c gene is implicated in focal progression of coronary artery disease. Atheroscler Thromb Vasc Biol 24 (2004) 551-557
8. Svensson P., De Faire U., Niklasson U., and Östergren J. Office blood pressure underestimates ambulatory blood pressure in peripheral arterial disease in comparison to healthy controls. J Hum Hypertens 18 (2004) 193-200
9. Gardner A.W., Skinner J.S., Cantwell B.W., and Smith L.K. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 23 (1991) 402-408
10. Rose G. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27 (1962) 645-658
11. Theodorsen L. Dry reagent technology. Kodak Ektachem 700 XR in clinical enzymology. Scand J Clin Lab Invest Suppl 215 (1993) 101-111
12. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
13. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
14. Levey A.S., and Greene T. Expressing the MDRD Study Equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values [abstract]. J Am Soc Nephrol 16 (2005) 69A
15. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 Suppl. 1 (2002) S1-S266
16. Roberts W.L., Sedrick R., Moulton L., Spencer A., and Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods:implications for clinical and epidemiological applications. Clin Chem 46 (2000) 461-468
17. Albert M.A., Rifai N., and Ridker P.M. Plasma levels of Cystatin C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 6 (2001) 145-149
18. Shi G.S., Sukhova G.K., Grubb A., et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104 (1999) 1191-1197
19. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
20. Volanakis J.E. Human C-reactive protein: expression, structure and function. Mol Immunol 38 (2001) 189-197
21. Liu J., Sukhova G.K., Sun J.S., et al. Lysosomal cystein proteases in atherosclerosis. Atheroscler Thromb Vasc Biol 24 (2004) 1359-1366
22. Chapman H.A., Reise R.J., and Shi G.P. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59 (1997) 63-88